

# Prakash Sampath

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/475957/publications.pdf>

Version: 2024-02-01

9  
papers

432  
citations

1684188

5  
h-index

2053705

5  
g-index

9  
all docs

9  
docs citations

9  
times ranked

818  
citing authors

#	ARTICLE	IF	CITATIONS
1	IMMU-39. FIRST-IN-KIND T CELLS CARRYING A CHIMERIC ANTIGEN RECEPTOR AGAINST AN EXTRACELLULAR MATRIX PROTEIN TARGET GLIOBLASTOMA CELLS AND SHOW ANTI-TUMOR EFFICACY. <i>Neuro-Oncology</i> , 2018, 20, vi129-vi130.	1.2	0
2	EXTH-44. TARGETING GLIOMA STEM CELLS WITH CAR-T IMMUNOTHERAPY IN XENOGRAFT ANIMAL MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi94-vi94.	1.2	0
3	Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells. <i>Cancer Letters</i> , 2018, 433, 131-139.	7.2	37
4	Updates On Chimeric Antigen Receptor-Mediated Glioblastoma Immunotherapy. <i>Rhode Island Medical Journal</i> (2013), 2017, 100, 39-42.	0.2	0
5	IMST-05. NOVEL CAR-T CELLS TARGETING THE EXTRACELLULAR MATRIX OF GLIOBLASTOMA INDUCE STRONG ANTI-TUMOR IMMUNE RESPONSE. <i>Neuro-Oncology</i> , 2016, 18, vi86-vi87.	1.2	0
6	Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	40
7	Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. <i>Neuro-Oncology</i> , 2014, 16, 1304-1312.	1.2	131
8	Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	100
9	Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells. <i>Clinical Cancer Research</i> , 2012, 18, 5949-5960.	7.0	124